NIH BOARD OF CONTRACT AWARDS REVIEW CHECKLIST NEGOTIATED ACQUISITIONS

(including R&D and Commercial Acquisition)

REVIEW TYPE									
() Presolicitation	() Preaward	()Postaward							
Office of Acquisition									
Awarding Office									
Presolicitation or Contract Number									
Contract Specialist									
Contracting Officer									
Total Price/Estimated Cost									
Period of Performance									
Brief Description of Items or Services Being Acqui	ired								

SECTION A – Acquisition Planning

No.	Action Item	FAR/HHSAR/	Yes	No	N/A	Comments
		NIH Policy Part				
		Acquisition				
A 1		Planning FAR 7.102				
A.1		FAR 7.102;				
	Was adequate market research	10.001, 10.002;				
	performed?	12.101 (over				
		\$100K); HHSAR				
		307.7105				
A.2	If RFI or exchanges with industry,	FAR 15.201				
	were they conducted properly?					
A.3	Does File contain an adequate	FAR 7.105;				
	Acquisition Plan (AP), addressing	HHSAR 307.71				
	all FAR and HHSAR requirements?	(>\$500K – but see				
	•	documentation				
		requirements for				
		<\$500K or other				
		exceptions at				
		307.7101(c))				
		HHS AP template				
A.4	Does AP discuss the rationale for	FAR 16.103				
7 1. 1	the contract type selected and is the	HHS AP template				
	type appropriate for the	THIS 711 template				
	requirement?					
A.5	Was acquisition plan developed by	FAR 7.102(b)				
A.3	1 1 1	FAR 7.102(b)				
	entire team and has each participant been identified in the AP?	FAK/.103				
A (EAD 7 105				
A.6	Did the Government develop an	FAR 7.105;				
	independent government cost	HHSAR 307.7103				
	estimate and is it adequate?					

No.	Action Item	FAR/HHSAR/	Yes	No	N/A	Comments
		NIH Policy Part				
A.7	Is there evidence of milestone	FAR 7.105(b)(20);				
	planning/scheduling?	HHSAR 307.7106				
A.8	If brand name description used,	FAR 6.302-1(c),				
	specifying a particular brand name,	6.302-1(d), 6.303,				
	product or feature of a product,	6.304				
	peculiar to one manufacturer, was					
	written justification prepared and					
	approved?					
A.9	If requirement is potentially	FAR 50.205-2(a)(3)				
	appropriate for Safety Act					
	protections, is there evidence in the					
	file that the program office obtained					
	pre-qualification notice?					
A.10	If funded with disaster assistance	FAR 3.1003(b)(2)				
	funds and requested by DHS, does					
	the acquisition include requirement					
	to display any fraud hotline poster					
	applicable to specific project?	*****				
A.11	Is there evidence of adequate	HHSAR 307.7104				
	funding or intent to commit funds?	******				
A.12	Does the file contain evidence of	HHSAR 307.170;				
	project officer required training or a	307.170-1				
	waiver?					
A 10	IC 1: 11 1 CO 1 1 1 2	EAD 22 1502				
A.13	If applicable, has CO checked the	FAR 22.1503				
	List of Products Requiring					
	Contractor Certification as to					
	Forced or Indentured Child Labor					
	(www.dol.gov/ilab/)?					

No.	Action Item	FAR/HHSAR/	Yes	No	N/A	Comments
		NIH Policy Part Small Business				
A.14	If exceeding specified thresholds, was acquisition plan coordinated with small business specialist (HHS-653)? If applicable, were proper appeal procedures followed?	FAR 7.104(d); HHSAR 319.501				
A.15	If CO rejects the SBS' or SBA PCR's recommendation, has the justification been documented on the HHS Form 653 and, if SBA PCR recommendation has been rejected, has the SBA PCR been notified?	FAR 19.202-1, FAR 19.505, HHSAR 319.501				
A.16	If this requirement was previously an SBSA, and its current size makes it unlikely for competition by SBs, or the requirement involves bundling, has coordination with SBA PCR taken place at least 30 days prior to release of RFP?	FAR 19.202- 1(e)(1); 19.501(f) FAR 10.001				
A.17	If 8(a) contract, has Offering Letter been sent to SBA?	FAR 19.804				
A.18	If 8(a) acquisition, does requirement meet the test for a single source 8(a) acquisition? If over the threshold, is the requirement set up as competitive?	FAR 19.805-1				
A.19	Has HUBZone set-aside been considered?	FAR 19.1305				

No.	Action Item	FAR/HHSAR/ NIH Policy Part	Yes	No	N/A	Comments
A.20	Has service-disabled veteran-owned small business (SDVOSB) set-aside been considered?	FAR 19.1405				
		Contract Type/Purchase Description/ SOW/SOO				
A.21	Is Purchase description/statement of work, specification, etc. adequate, encouraging competition or ensuring fair opportunity process, properly describing commercial products/services, if applicable, limiting use of "brand name or equal" unless justified, and following established purchase description order of preference?	FAR 11.002, 11.101(a)				
A.22	If brand name or equal, does the purchase description cover the salient physical, functional or performance characteristics of brand name?	FAR 11.104				
A.23	If requirement is for electronic products, are the Electronic Product Environmental Assessment Tool (EPEAT) standards being used?	FAR 23.705				

No.	Action Item	FAR/HHSAR/	Yes	No	N/A	Comments
		NIH Policy Part				
A.24	Did requirements documents	FAR 11.101,				
	achieve maximum practicable	FAR 23.2, 23.4,				
	energy efficiency as well as use of	23.7				
	recovered material, environmentally					
	preferable materials, energy- and					
	water-efficient products, renewable					
	energy technologies, products					
	containing energy-efficient standby					
	power devices, ENERGY STAR or					
	FEMP products as required, and					
	biobased products, as applicable?					
A.25	If Government property to be	FAR 45.102				
	furnished to contractor, were the					
	criteria at FAR 45.102 met?					
		OCOI/COI				
A.26	If potential for OCOI determined,	FAR 9.504(b)				
	has CO obtained assistance/advice					
	of legal counsel and technical					
	specialists in evaluating potential					
	conflicts?					
A.27	If significant potential COI, has CO	FAR 9.504(c)				
	provided written analysis,					
	recommended course of action, and					
	draft RFP provision and contract					
	clause?					

No.	Action Item	FAR/HHSAR/	Yes	No	N/A	Comments
		NIH Policy Part				
		Noncompetitive				
		Contracts				
A.28	Has market research been	FAR 10.002(b)(2)				
	accomplished to ensure that a					
	noncompetitive contract is					
1.20	necessary?	E+B < 202.1				
A.29	If other than full and open	FAR 6.303-1				
	competition, has JOFOC been	HHSAR 306.303-				
	prepared and approved?	1, JOFOC Desk				
		Guide				
		Service Contract				
A.30	If Service Contract Act (SCA) is	FAR 22.1002,				
	not applicable, is the rationale	22.1008-1				
	adequately documented, or if SCA					
	is applicable, is wage determination					
	in the file or being requested via					
	e98 process?	7.5.7.20				
A.31	Is there documentation that the	FAR 7.503;				
	services, if applicable, do not	11.106				
	represent an inherently					
	governmental function?	7.7.7.407				
A.32	If services, has a performance-	FAR 7.105,				
	based acquisition (PBA), including	37.102, 37.6;				
	PBA SOW, been written and has	HHSAR 307.105				
	the acquisition plan discussed the	HHS AP				
	strategies for implementing a					
	performance-based acquisition					
	(including associated measures,					
	incentives, if any, and quality					
	surveillance plan)?					

A.33	If PBA for services and other than a firm-fixed price basis, has rationale been documented?	FAR 7.105(b)(4)			
A.34	If services, and PBA is not being contemplated, has the AP addressed the rationale for not using PBA?	FAR 7.104, 37.102, 37.6, HHS AP HHSAR 307.7105			
A.35	Does AP address bundling and was market research conducted to determine whether bundling was necessary and if so, was it justified and approved?	FAR 7.107			
A.36	If bundled contract, has notification to affected incumbent SB concerns taken place?	FAR 10.001(c)(1) & (2)			
A.37	Has coordination of anticipated bundled contract taken place with HHS SBS and PCR?	FAR19.202- 1(e)(1)(iii)			
		Sources			
A.38	Has use of priority sources and existing contracts (FSS, IDIQ, GWACs) been considered?	FAR 8.002			
A.39	If purchasing supplies of the classes listed in the FPI Schedule, was market research conducted to determine comparability with FPI item and written determination made?	FAR 8.602(b) (required > \$3.000)			

No.	Action Item	FAR/HHSAR/ NIH Policy Part	Yes	No	N/A	Comments
		EIT/EPA				
A.40	If acquiring EIT supplies/services, was Section 508 compliance assured or exception documented?	FAR 39.203				
A.41	If requirement includes EPA designated items or services that contain recovered material (>10K), was compliance assured or exception documented? (see http://www.epa.gov/cpg)	FAR 23.405				
A.42	If requirement includes USDA designated items containing biobased products or materials (http://www.usda.gov/biopreferred) has compliance been ensured or exception documented?	FAR 23.405(a)(2)				
		R&D Issues				
A.43	If R&D, is there evidence of peer review of concept and 75% of reviewers were/will be non-Government?	HHSAR 315.305(a)(3)(ii) (F), NIH Manual 6315-1				
		IT Issues				
A.44	If IT requirement, have agency planners complied with capital planning and investment control requirements in 40 USC 11312 and OMB Circular A-130?	FAR 7.103(t)				

No.	Action Item	FAR/HHSAR/ NIH Policy Part	Yes	No	N/A	Comments
A.45	If IT requirement, are IT security requirements in FISMA, OMB's implementing policies (including Appendix III of OMB Circular A-130) and NIST guidance and standards being followed?	FAR 7.103(u), 39.101, 39.106				
A.46	If commercial IT is being acquired, has exemption from Buy American Act been assured?	FAR 25.103(e)				
A.47	If IT requirement, are appropriate IT security policies and requirements, including use of common security configurations available from NIST at http://checklists.nist.gov incorporated in RFP?	FAR 39.101(d)				
	-	D&Fs				
A.48	If IDIQ >100M, is D&F approved by HCA in file?	FAR 16.504(c)(1)(ii) (D)				
A.49	If applicable, is there an approved D&F for use of a T&M or LH contract?	FAR 16.601(c)				
A.50	If applicable, is there a properly approved D&F for use of a letter contract?	FAR 16.603-3(a), HHSAR 316.603- 3, OAMP Policy Letter 2004-01				
A.51	If multi-year contracting used, has HCA determination been obtained?	FAR 17.105-1				

No.	Action Item	FAR/HHSAR/ NIH Policy Part	Yes	No	N/A	Comments
A.52	If a particular source has been excluded from contract action to establish or maintain alternative source/sources, has determination been made and approved?	FAR 6.202(b)				
A.53	If contract action is with a Government employee or business concern substantially owned/controlled by one or more Government employees, has HCA authorized exception?	FAR 3.602, HHSAR 303.602				
A.54	If applicable, has D&F been executed for evaluation or non-evaluation of options?	FAR 17.206				
A.55	If commercial item time and materials or labor-hours contract is being contemplated, has D&F been executed?	FAR 12.207(b)				
A.56	If commercial item acquisition for items >\$100K and <\$5.5M (or >\$11M for acquisitions described in FAR 13.500(e)), have simplified procedures been used under Test Program, or has file documented rationale for not using these procedures?	FAR 12.203, 13.5				
A.57	If firm-fixed price, level-of-effort contract (>\$100K) used, has Chief of Contracting Office approved?	FAR 16.207-3(d)				

No.	Action Item	FAR/HHSAR/	Yes	No	N/A	Comments
		NIH Policy Part				
A.58	If applicable, has Buy American	FAR				
	Act determination been made and	25.102(b)(2),				
	approved?	HHSAR				
		325.102(a)				
A.59	If submission of cost/pricing data	FAR 15.403-4(a)				
	>SAT but <\$650K, has approval					
	been obtained?					
A.60	If RFP is to include Quantity	FAR 36.516				
	Surveys, (FAR 52.236.16, Alt. 1),					
	has determination been made at one					
	level above CO?					
A.61	If liquidated damages planned, are	FAR 11.5				
	they adequately documented as to					
	their need, and not considered a					
	penalty?					
A.62	If acquisition meets the definition	FAR Part 18				
	of "emergency acquisition					
	flexibilities" have the available					
	acquisition flexibilities or					
	emergency flexibilities been					
	considered, and if not, has the					
	action as written been justified as to					
	rationale for not using these					
1 50	flexibilities?	EAD 10.005()				
A.63	If commercial IDIQ contract ONLY	FAR 12.207(c)				
	allows T&M or L/H orders, has					
	determination been made					
	explaining why firm-fixed-price or					
	fixed-price with economic price					
	adjustment was not practical?					

No.	Action Item	FAR/HHSAR/ NIH Policy Part	Yes	No	N/A	Comments
A.64	Did CO determine insurance levels against loss of or damage to Government property and need for bonds?	FAR 28.306(b)(1)				
A.65	If warranties determined appropriate, did CO consider criteria for use, are limitations stipulated and has approval been obtained?	FAR 46.703, 46.705, 46.704				
		Synopsis				
A.66	If no FAR exception, FedBizOpps (FBO) notice been properly published?	FAR 5.101 (>\$25,000), 5.202, 5.203(a) (may be < 15 days-commercial items)				
A.67	If subject to Trade Agreements Act (TAA), has proper note been included in Synopsis?	FAR 25.408(b)				
A.68	If CO believes that advance notice is not appropriate, has memo requesting relief from synopsizing been approved by HHS?	HHSAR 305.202				
A.69	If brand name specifications, did CO include justification or documentation required in FBO?	FAR 6.302-1(c), 13.501, OFPP memo 4/17/06				
A.70	If notice in GPE (i.e., FBO) is not required, is file documented re: use of brand name specifications?	FAR 11.105, OFPP Memo 4/17/06				

No.	Action Item	FAR/HHSAR/	Yes	No	N/A	Comments
		NIH Policy Part				
A.71	If noncompetitive acquisition	FAR 5.201,				
	requiring synopsis, was it properly	6.302; 6.4, 6.5;				
	documented, issued in FedBizOpps	HHSAR 306.2,				
	or is a draft synopsis in the file?	205.3, 206.5				
A.72	If commercial item and streamlined	FAR 12.603(c)				
	procedures (combined					
	synopsis/solicitation), was synopsis					
	prepared properly?					
A.73	If Safety Act is applicable, does	FAR 50.205-2(b)				
	pre-solicitation notice state that pre-					
	qualification designation notice has					
	been requested and either issued or					
	denied by DHS? If designation					
	notice has been issued, has it been					
	incorporated into RFP?					
		Evaluation				
		Planning				
A.74	Are evaluation factors and	FAR 15.304(b)(1)				
	significant subfactors tailored to	HHSAR 315.204-				
	acquisition and do they represent	5(c)(2)				
	the key areas of importance and					
	emphasis to be considered?					
A.75	Is price or cost an evaluation factor?	FAR 15.304(c)(1)				
A.76	Do evaluation factors and	FAR 15.304(c)(2)				
	significant subfactors address					
	quality of product/service?					

No.	Action Item	FAR/HHSAR/ NIH Policy Part	Yes	No	N/A	Comments
A.77	Does RFP include a statement that indicates, at a minimum, whether all evaluation factors, other than cost or price, when combined, are significantly more important, approximately equal in importance, or significant less important, than cost or price?	FAR 15.304(e)				
A.78	Is past performance an evaluation factor or is there documentation in the file as to why past performance will not be considered?	FAR 15.304(c)(3)(ii), HHSAR 315.204- 5(c)(3) (competitive >\$100K)				
A.79	Did evaluation factors and significant subfactors include extent of participation of SDB concerns in performance of the contract?	FAR 15.304(c)(4)				
A.80	If bundling and significant subcontracting opportunities exist, do evaluation factors/subfactors assure evaluation of offeror's past attainment of SB goals?	FAR 15.304(c)(3)(iii)				
A.81	If bundling and significant subcontracting opportunities exist, do evaluation factors/subfactors include evaluation of proposed SB goals in offeror's subcontracting plan?	FAR 15.304(c)(5)				

No.	Action Item	FAR/HHSAR/ NIH Policy Part	Yes	No	N/A	Comments
A.82	Do evaluation factors/subfactors	FAR				
	assure that offerors are not	15.304(c)(6),				
	unfavorably evaluated if	7.108(b)				
	telecommuting included, unless it					
	prohibited and CO executed					
	determination ?					
A.83	Does RFP clearly state all factors	FAR 15.304(d),				
	and subfactors and their relative	HHSAR 315.204-				
	importance?	5(c)(1)				
		IDIQs				
A.84	If IDIQ, are multiple awards	FAR 16.504(c)				
	anticipated, or does the file justify					
	why a single award is					
	contemplated?					
A.85	If IDIQ, have procedures for	FAR 16.504				
	ordering been included?					
A.86	If IDIQ, have minimum and	FAR 16.504				
	maximum quantities been included?					
A.87	If IDIQ, has period of performance	FAR 16.504				
	been included?					
		Misc. Issues				
A.88	Does the RFP include time of	FAR 11.4				
	delivery or performance schedule?					
A.89	If commercial item acquisition for	FAR 12.203, 13.5				
	items >\$100K and <\$5.5M, have					
	simplified procedures been used					
	under Test Program, or has file					
	documented rationale for not using					
	these procedures?					

No.	Action Item	FAR/HHSAR/ NIH Policy Part	Yes	No	N/A	Comments
A.90	If acquisition is for printing, are the requirements of NIH Manual Chapter 6308 being followed?	NIH Manual Chapter 6308				
A.91	If lease, is there a record of a lease or buy determination?	FAR 7.401				
A.92	If contract involves safety/health issues, are proper clauses included?	HHSAR 323.7002				
A.93	If contract involves animals, are proper clauses and language included in RFP?	HHSAR 370.4. 352.270-9, HHS AP, NCI RFP Workforms				
A.94	If contract involves human subjects, are proper clauses and language included in RFP?	HHSAR 370.3, 352.270-8, HHS AP, NCI RFP Workform (DGS)				
A.95	If advisory multi-step process, is there compliance with procedures?	FAR 15.202				
A.96	If applicable, when Earned Value Management System is to be used, has the AP complied with procedures?	FAR 7.105(b)(3), (10), FAR 34.2; HHS Earned Mgmt. Value Policy, OCIO Policy for IT EVM Procedures				
A.97	If bonds and/or insurance required, is there compliance with regulations/procedures?	FAR 28.3				

No.	Action Item	FAR/HHSAR/	Yes	No	N/A	Comments
		NIH Policy Part				
A.98	Does acquisition meet test to be	FAR				
	considered commercial item under	12.102(f)(1),				
	defense against or recovery from	12.102(g)(1), 18.2				
	nuclear, biological, chemical or	_				
	radiological attack, or does it meet					
	the test under FAR 12.102(g)(1)?					
A.99	Is there evidence of an internal file	NIH Manual				
	review?	Chapter 6304.71				

SECTION B – SOLICITATION PHASE

No.	Action Item	FAR/HHSAR/ NIH Policy Part	Yes	No	N/A	Comments
		RFP				
B.1	Is uniform contract format used (if	FAR 15.204-1				
	no exception under FAR 15.204)?	(unless exempt by				
B.2	For commercial item acquisition, is prescribed format used and is the cover page an SF 1449?	FAR 15.204) FAR 12.303				
B.3	Does RFP include proper NAICS code and size standard?	FAR 19.303(a)				
B.4	Is solicitation period consistent with FAR 5.203?	FAR 5.203				
B.5	If not commercial, does RFP include annual reps and certs provision?	FAR 4.1202 and 52.204-7				
B.6	If electronic commerce was used to issue RFP and receive proposals, did RFP specify permitted electronic methods?	FAR 15.203(c)				
B.7	Are proper provisions included?	FAR 52.301 Matrix, NCI RFP Workform				

No.	Action Item	FAR/HHSAR/	Yes	No	N/A	Comments
		NIH Policy Part				
B.8	Are proper clauses included?	FAR 52.301				
		Matrix, NCI				
		Contract				
		Workform				
B.9	If SCA is applicable, does RFP	FAR 22.1007,				
	contain the proper wage	FAR 22.1009,				
	determination and clauses?	22.1016				
B.10	If required, does the RFP contain	FAR 22.1002				
	the proper wage determination or a					
	statement that it will be included					
	later, and is proposed contract					
	limited to 5 years or less?					
B.11	If oral RFP used, is there	FAR 15.203(f)				
	compliance with FAR?					
B.12	If letter contract and a sole source	FAR 15.203(e)				
	acquisition, is there compliance					
	with FAR?					
B.13	If purchasing supplies of classes	FAR				
	listed in Federal Prison Industries	8.602(a)(4)(ii)				
	(FPI) Schedule but not determined					
	comparable based on market					
	research, has the RFP been					
	provided to FPI (unless available					
	through FedBizOpps)?					
B.14	If Qualified product, have FAR	FAR 9.2, 14.210				
	requirements been followed?					
B.15	If liquidated damages, is the clause	FAR 11.503				
	proper?					

No.	Action Item	FAR/HHSAR/ NIH Policy Part	Yes	No	N/A	Comments
B.16	If brand name specifications used, did CO include with the RFP required justification or documentation?	FAR 6.302-1(c)				
B.17	If potential conflict of interest is involved, does RFP include appropriate provisions?	FAR 9.504(b), 9.506(b)(1)-(3), NIH Manual 6009-1				
B.18	If contractor will have physical access to a federally-controlled facility or access to a federal information system, has FIPS PUB 201, associated OMB guidance, and requirement for inclusion of proper provision/clause been followed?	FAR 4.13 and 52.204-9				
B.19	If hazardous materials required, has FAR 52.223-3 been included?	FAR 23.303(a)				
B.20	Are date, place and time for receipt of offers clearly stated on face page of RFP?	FAR 15.204-2				
B.21	If required, has solicitation included requirement for bonds/insurance?	FAR 28				

No.	Action Item	FAR/HHSAR/	Yes	No	N/A	Comments
		NIH Policy Part				
B.22	If CO determined that RFP	FAR 5.102(a)(4);				
	contained information that required	5.102(a)(5)				
	additional controls to monitor	(over \$25K)				
	access and distribution (e.g.,					
	technical data, specifications, maps,					
	building designs, schedules, etc.),					
	was information made available					
	through the Federal Technical Data					
	Solution (FedTeDS) unless exempt?					
B.23	If FedTeDS was used, did it meet	FAR 5.102(a)(4)				
	FBO synopsis and advertising					
	requirements?					
B.24	Does the RFP include requirement	FAR 3.10				
	for contractor code of business ethic					
	and conduct, and a hotline poster					
	display, as applicable?					
B.25	If brand name specifications used,	FAR 6.302-1(c)				
	did RFP include required					
	justification or documentation?					
		RFP				
		Amendments				
B.26	If oral notice of RFP amendment, is	FAR 15.206(f)				
	there compliance with FAR?					
B.27	If RFP is amended, have	FAR 15.206				
	amendments been sent to all parties					
	receiving the RFP and was closing					
	date extended if necessary?					
B.28	If modification of wage	FAR 22.404-6,				
	determination – has it been handled	22.407(a)(8)				
	properly in RFP?					

No.	Action Item	FAR/HHSAR/ NIH Policy Part	Yes	No	N/A	Comments
		Evaluation				
B.29	If human subjects, women and minorities, children, Data Safety Monitoring Boards (DSMBs), HIV antiretroviral treatment trials in developing countries, generation of research data, biomedical research of model organisms are involved, are proper clauses included and do evaluation criteria reflect how this will be rated?	NIH Manual 6315-1, NCI RFP Workform				
B.30	Does RFP include factors and significant subfactors to be used to evaluate proposals, and their relative importance?	FAR 15.203(a)(3), HHSAR 315.204- 5(c)				
B.31	If applicable, has a price evaluation adjustment for HUBZone concerns been included?	FAR 19.1307				
B.32	If applicable, has a price evaluation adjustment for SDB concerns been included?	FAR 19.1307				
B.33	If Government property offered, does RFP include evaluation procedures to be followed and require submittal of stated information with offerors' proposals?	FAR 45.201(c)				
B.34	Does RFP provide basis for award?	FAR 15.304				

No.	Action Item	FAR/HHSAR/ NIH Policy Part	Yes	No	N/A	Comments
		Options				
B.35	If options included, does the RFP	FAR 17.203(b),				
	provide the basis for evaluation?	HHSAR 317.201				
B.36	If options included, does the RFP	FAR 17.204(e),				
	limit the term to 10 years for	HHSAR				
	services (except those subject to	317.204(e)				
	SCA - 5 years), and 5 years for					
	supplies? (N/A for IT contracts and					
	R&D contracts)					
B.37	If options included, is provision at	FAR 17.202(a)				
	FAR 52.217-5 included?					
B.38	If option to extend term of contract	FAR 22.404-12				
	is included, did RFP include a					
	method to provide allowance for					
	increases/decreases in labor costs					
	resulting from inclusion of current					
	WDs upon exercise of options?					
		IDIQ				
B.39	If IDIQ contract contemplated, are	FAR 16.5				
	multiple awards being made or is					
	there a justification for a single					
	award?					
B.40	Does the RFP specify the period of	FAR 16.504(a)				
	performance, the minimum and					
	maximum quantities, procedures for					
	fair opportunity, etc. necessary					
	under IDIQ contracts?					

No.	Action Item	FAR/HHSAR/	Yes	No	N/A	Comments
		NIH Policy Part				
		Commercial				
		Item				
B.41	Does acquisition meet test to be	FAR				
	considered commercial item under	12.102(f)(1),				
	defense against or recovery from	12.102(g)(1)				
	nuclear, biological, chemical or					
	radiological attack, or does it meet					
	the test under FAR $12.102(g)(1)$?					
B.42	If a commercial item, is RFP in the	FAR 12.303				
	proper format with proper clauses?					
B.43	If commercial item, does RFP	FAR 12.205(a)				
	request existing literature instead of					
	unique technical proposals?					
B.44	If commercial item, and combined	FAR 12.603				
	synopsis/solicitation was used, does					
	it contain appropriate information?					
B.45	If commercial IT acquired, is	FAR 25.103(a)				
	exemption from Buy American Act					
	assured?					
B.46	If commercial item acquisition, will	FAR 12.207				
	award be a firm-fixed-price or					
	fixed-price with economic price					
	adjustment, or if properly executed					
	D&F in file, and contract provides					
	for a ceiling price, on a time-and-					
	materials or labor-hour basis?					
B.47	If commercial item, and tailoring of	FAR 12.302				
	RFP provisions has taken place, is it					
	compliant?					

No.	Action Item	FAR/HHSAR/ NIH Policy Part	Yes	No	N/A	Comments
B.48	If commercial item, has a commercial quality assurance system been accepted?	FAR 12.208				
B.49	If commercial item, as applicable, are technical data requirements compliant?	FAR 12.211				
B.50	If commercial item, as applicable, are computer software requirements compliant?	FAR 12.212				
		Cost/Price				
B.51	Does RFP adhere to pricing policy and used order of precedence for determining type of cost or pricing data required? Did CO comply with prohibition on obtaining cost or pricing data?	FAR 15.402, 15.403-1				
B.52	If RFP will waive requirement for cost or pricing data, has HCA approved waiver?	FAR 15.403- 1(c)(4)				
B.53	If RFP will require submission of cost or pricing data >100K but <\$550K, has HCA authorized CO to obtain the data?	FAR 15.403- 4(a)(2)				
B.54	Does RFP include instructions for submission of cost or pricing data or other than cost or pricing data (information)?	FAR 15.403(5)(a)(1)- (4)				

No.	Action Item	FAR/HHSAR/ NIH Policy Part	Yes	No	N/A	Comments
B.55	If submission of cost or pricing data is required, does RFP state that such data can be submitted in offeror's own format?	FAR 15.403- 5(b)(2) (unless CO determines a specific format is essential)				
B.56	If cost-reimbursement contract is used, is RFP appropriately structured as Level of Effort or Completion type and is proper language used?	FAR 35.005(c)				
B.57	If RFP will require submission of cost or pricing data >100K but <\$650K, has HCA authorized CO to obtain the data?	FAR 15.403- 4(a)(2)				
B.58	If EVMS is required (for major acquisitions for development IAW OMB Circular A-11, Part 7 and Supplement to Part 7, Capital Programming Guide) did RFP include proper clauses and procedures?	FAR 34.203(a)-(d)				
B.59	If Government property was offered, did RFP include listing of property with minimum information specified?	FAR 45.201(a)				

No.	Action Item	FAR/HHSAR/ NIH Policy Part	Yes	No	N/A	Comments
B.60	If Government property was offered in competitive acquisition, did RFP specify that contractor is responsible for all costs related to making property available for use?	FAR 45.201(b)				
B.61	If Government property was offered, did RFP include evaluation procedures to be followed and require offerors to submit specified information with their proposal?	FAR 45.201(c)				
B.62	If use of Government property was anticipated on more than one contract, did SOW include additional instructions regarding property management, accountability and use?	FAR 45.201(d)				
		Multi-Year Contracting				
B.63	If multi-year contracting used, did RFP include all required factors to be considered in evaluation?	FAR 17.106-2				
B.64	If multi-year contracting used, did RFP include required clauses?	FAR 17.109				

No.	Action Item	FAR/HHSAR/	Yes	No	N/A	Comments
		NIH Policy Part				
		MISC. ISSUES				
B.65	If PBA methods used, is a	FAR37.604,				
	Performance Work Statement	46.401(a)				
	(PWS) or Statement of Objectives					
	(SOO) included in RFP, as well as a					
	Quality Assurance Surveillance					
	Plan (either in RFP or to be					
	developed by offeror)?					

SECTION C - RECEIPT, EVAUATION AND AWARD

No.	Action Item	FAR/HHSAR/	Yes	No	N/A	Comments
110.	Action Item	NIH Policy Part	165	110	1 \ //A	Comments
		•				
G 1	***	Receipt				
C.1	Have proposals been received no	FAR 15.208,				
	later than time set for receipt of	HHSAR 315.208				
	offers, and if not, are late proposals					
	handled properly?					
C.2	Are proposal modifications,	FAR 15.208,				
	revisions, or withdrawals handled	HHSAR 315.208				
	properly?					
C.3	If proposal from FPI received, was	FAR				
	it timely and if so, was it properly	8.602(b)(4)(ii)				
	considered?					
C.4	If electronic proposals were	FAR 15.203(c)				
	permitted, were any unreadable					
	electronic bids handled properly?					
		Evaluation				
C.5	If R&D was composition of	HHSAR				
	technical evaluators proper?	315.305(a)(3)(ii)				
		(F), NIH Manual				
		6315-1				
C.6	If unsolicited proposal, were	FAR 15.6,				
	procedures appropriately followed?	HHSAR 315.6				
C.7	If R&D was ALERT System notice	NIH Manual				
	provided?	6309-1				
C.8	Do at least 50% of HHS evaluators	HHSAR 307.170-				
	have appropriate training?	2				
C.9	If past performance is an evaluation	FAR 15.305				
	factor, has it been properly					
	evaluated? Has					
	http://www.ppirs.gov/ been used to					
	check past performance?					

No.	Action Item	FAR/HHSAR/	Yes	No	N/A	Comments
		NIH Policy Part				
C.10	Was technical evaluation conducted	FAR				
	in accordance with stated evaluation	15.305(a)(1),				
	factors?	15.404-1(a)-(c)				
C.11	Were any restrictions on disclosure	HHSAR				
	of descriptive literature handled	315.305(a)(3)(ii)				
	properly?	(F)(3)				
C.12	Were restrictions on use of support	FAR 15.305(c),				
	contractor personnel for proposal	37.203(d)				
	evaluation (other than R&D)					
	complied with?					
C.13	Was cost information furnished to	FAR				
	members of technical panel?	15.305(a)(4),				
		15.404-1(e)				
C.14	If option quantities or periods were	FAR 17.206				
	solicited, was proper evaluation					
	conducted?					
C.15	If commercial item, are commercial	FAR 12.208,				
	quality assurance system, technical	12.211, 12.212				
	data requirements, and/or computer					
	software requirements acceptable					
	and compliant?					
C.16	Did proposal evaluation consider	FAR 45.202(a)				
	any potentially unfair competitive					
	advantage resulting from possession					
	of Government property by					
	adjusting offers by applying (for					
	evaluation purposes only) a rental					
	equivalent?					

No.	Action Item	FAR/HHSAR/ NIH Policy Part	Yes	No	N/A	Comments
C.17	If Government property is to be used by contractor, did CO ensure that offeror's property management plans, methods, practices, or procedures for accounting for the property were consistent with RFP requirements?	FAR 45.202(b)				
C.18	Are evaluators' certifications in file?	HHSAR 315.305(a)(3)(ii)(E)(2) and (3)				
C.19	Is a technical evaluation report in the file and does it contain a report of relative strengths and weaknesses of each offeror?	FAR 15.305, HHSAR 315.305(a)(3)(vi)				
C.20	Was small business subcontracting evaluation accomplished properly?	FAR 15.305(a)(5)				
C.21	Has the Project Officer completed the Project Officer Technical Evaluation Questionnaire and have his/her comments been taken into account during negotiations?	HHSAR 315.306, NIH Manual 6015-1 and 6315- 1				
C.22	Is cost or price evaluation compliant?	FAR 15.305(a)(3), 15.404-1(a)-(c), HHSAR 315.305				
C 22	If award to be used without	Communications				
C.23	If award to be made without discussions, were exchanges limited to clarifications?	FAR 15.306(a)				

No.	Action Item	FAR/HHSAR/ NIH Policy Part	Yes	No	N/A	Comments
C.24	Have communications held with offerors before establishment of competitive range been compliant?	FAR 15.306				
		Competitive Range				
C.25	Has competitive range determination been sufficiently documented?	FAR 15.306(c)				
C.26	Has notice been given to offerors excluded from competitive range or otherwise eliminated from competition?	FAR 15.503(a)(1)				
		Discussions				
C.27	Have exchanges with offerors after establishment of competitive range followed stipulated procedures?	FAR 15.306(d) and (e), HHSAR 316.306(d)				
C.28	Have proposal revisions/final proposal revision been handled properly?	FAR 15.307, HHSAR 315.307				
C.29	Have any finalization of details with the selected source taken place, and if so, are they in accordance with established guidelines?	HHSAR 315.370				
		Cost Analysis				
C.30	Has cost analysis, price analysis, cost realism been performed as required?	FAR 15.404, HHSAR 315.404- 2				

No.	Action Item	FAR/HHSAR/	Yes	No	N/A	Comments
		NIH Policy Part				
C.31	If cost analysis report has been	FAR Part 15, NIH				
	provided from DFAS or through	Manual 6015-1				
	field pricing information, have					
	recommendations been followed or					
	has the file been documented					
	justifying why the					
	recommendations were not					
	followed?					
C.32	If cost analysis was performed, is	FAR 31.202;				
	there adequate evaluation of	OMB Circular A-				
	negotiated direct labor costs?	21				
C.33	If cost analysis was performed, is	FAR 31.202;				
	there adequate evaluation of	OMB Circular A-				
	negotiated fringe benefit costs?	21				
C.34	If cost analysis was performed, is	FAR 31.202;				
	there adequate evaluation of	OMB Circular A-				
	negotiated materials and supplies	21				
	costs?					
C.35	If cost analysis was performed, is	FAR 31.202;				
	there adequate evaluation of	OMB Circular A-				
	negotiated other direct costs?	21				
C.36	If cost analysis was performed, is	FAR 31.202;				
	there adequate evaluation of	OMB Circular A-				
	negotiated indirect costs?	21				
C.37	If applicable, was the Salary Rate	NIH Manual				
	Limitation correctly applied and is	6030-1				
	the Salary Rate Limitation clause					
	included in the contract?					
C.38	Has subcontract pricing been	FAR 15.404-3				
	appropriately considered?					

No.	Action Item	FAR/HHSAR/ NIH Policy Part	Yes	No	N/A	Comments
C.39	If applicable, has profit been adequately analyzed?	FAR 15.404-4, HHSAR 315.404-				
C.40	If cost or pricing data was required, did contractor execute a proper Certificate of Current Cost or Pricing Data?	FAR 15.406-2				
C.41	If cost or pricing data waived, is waiver in accordance with stipulated guidelines?	FAR 15403- 1(c)(4)				
C.42	If CO learned that any cost or pricing data was inaccurate, incomplete, or noncurrent, is there compliance with procedures in FAR?	FAR 15.407-1				
		Negotiations				
C.43	Have prenegotiation objectives, including profit or fee analysis, been established?	FAR 15.406-1, HHSAR 315.404-				
C.44	Were written final proposal revisions requested with common cut-off date?	FAR 15.307				
		Award				
C.45	If applicable, have procedures for Trade Agreements Act (TAA) acquisitions been followed and have the proper notifications to unsuccessful WTO offerors been prepared?	FAR 25.408; FAR 25.5				

No.	Action Item	FAR/HHSAR/ NIH Policy Part	Yes	No	N/A	Comments
C.46	Are all required clauses included in contract?	FAR Matrix NCI Workform (DGS)				
C.47	Has CO resolved any conflict, or potential conflict of interest before contract award?	FAR 9.506(d), 9.503				
C.48	If conflict of interest existed that could not be avoided or mitigated, did CO notify contractor, provided the reasons, and allow the contractor a reasonable period to respond?	FAR 9.504(e)				
C.49	If CO found that it was in the best interests of the Government to award a contract notwithstanding a COI, was a written waiver obtained?	FAR 9.503, 9.504(e)				
C.50	If PBA, did CO ensure that contract includes a PWS, measurable performance standards, a method of assessing contractor performance against performance standards, and performance incentives, if appropriate?	FAR 37.601				
C.51	If FPI item determined to provide best value to the Government as a result of FPI's response to RFP, were proper ordering procedures followed?	FAR 8.602(a)(4)				

No.	Action Item	FAR/HHSAR/	Yes	No	N/A	Comments
		NIH Policy Part				
C.52	If applicable, has Buy American	FAR				
	Act determination been made and	25.103(b)(2),				
	approved?	HHSAR				
		325.102(a)				
C.53	If applicable, were offerors	FAR 22.10				
	provided current wage					
	determination prior to submission					
	of final proposal revision?					
C.54	Has price reasonableness been	FAR 15.406-3,				
	established, based on adequate price	HHSAR 315.372				
	competition, prices set by law or					
	regulation, commercial items?					
C.55	Is an adequate, signed negotiation	FAR 15.406-3,				
	memorandum ("Summary of	HHSAR 315.372				
	Negotiations") in the file?					
C.56	Does Summary of Negotiations	FAR 15.406-				
	adequately address negotiated	3(a)(7),(8),				
	amounts for each contract period?	HHSAR				
		315.372(g)				
C.57	Is Summary of Negotiations	FAR 15.406-				
	internally consistent with the	3(a)(7), (8);				
	cost/price amounts for each contract	HHSAR				
	period and with the contract	315.372(g)				
	document?					
C.58	If Facilities Capital Cost of Money	FAR 31.205-10				
	was proposed/negotiated, was a					
	dollar-for-dollar offset made to fee					
	or profit objective?					

No.	Action Item	FAR/HHSAR/ NIH Policy Part	Yes	No	N/A	Comments
C.59	Was affirmative determination of responsibility (including financial responsibility) made?	FAR 9.103(b), 9.104-1; HHSAR 315.372				
C.60	Is there adequate documentation in file to support responsibility determination (e.g, current balance sheet analysis with financial ratios computed, a current D&B report, line of verifications, etc.)?	FAR 9.104-1				
C.61	If non-responsible offer from small business, was nonresponsibility determination referred to SBA??	FAR 9.103				
C.62	If protest before award, was it handled properly?	FAR 33.1, NIH Manual 6033-1 and 6033-2				
C.63	If agency protest, were OGC and NIH PCO consulted and did they concur with response prepared by contracting officer?	HHSAR 333.103,				
C.64	Was Excluded Parties List System (EPLS) checked?	FAR 9.405(d)(1) & (4)				
C.65	If award being made to country identified on List of Products Requiring Contractor Certification as to Forced or Indentured Child Labor (www.dol.gov/ilab/) has proper certification been obtained?	FAR 22.1503				

No.	Action Item	FAR/HHSAR/	Yes	No	N/A	Comments
		NIH Policy Part				
C.66	Was proper notification provided to	FAR				
	unsuccessful offerors? If SBSA	15.503(a)(2)(i)				
	was there a proper preaward notice	(A)-(D)				
	to offerors unless CO made	(Required if				
	determination of urgency?	conditions exist)				
C.66	Was there an approved	FAR 19.702)a)(2)				
	subcontracting plan, if applicable?	(req. for LB				
		award over				
		\$550K)				
C.68	If subcontracting plan is applicable,	FAR 19.705-				
	has it been included as a part of the	5(a)(5)				
	contract?					
C.69	Was EEO Clearance received?	FAR 22.805				
		(required >\$10M				
		exc. Construction				
C.70	Are contractor's Representations	FAR 15.204-5				
	and Certifications complete and					
	accurate?					
C.71	If applicable, are performance-	FAR 32.1004(b),				
	based finance payments established	32.104				
	in contract only to extent actually					
	needed for performance?					
C.72	If performance/payment bond	FAR 28.103-1				
	required, are they in the file and					
	documented?					
C.73	Is there written assurance that	FAR 32.702,				
	adequate funds are available (funds	32.703-2				
	certification), or is the award					
	conditioned upon availability of					
	funds?					

No.	Action Item	FAR/HHSAR/	Yes	No	N/A	Comments
~ = 1		NIH Policy Part				
C.74	Is contract signed by a warranted	FAR 1.601, 4.101				
	CO within his/her authority?					
C.75	Was preaward notice furnished to	FAR				
	offerors if SDB concern received	15.503(a)(2)(i)				
	benefit based on disadvantaged	(B),				
	status, or if using HUBZone	15.503(a)(2)(i)				
	procedures, or if using service-	(C),				
	disabled veteran owned procedures?	15.503(a)(2)(i)				
		(D)				
C.76	If PBA, did CO ensure that contract	FAR 37.601				
	includes a PWS, measurable					
	performance standards, a method of					
	assessing contractor performance					
	against performance standards, and					
	performance incentives, if					
	appropriate?					
C.77	If EVMS was required, did award	FAR 34.203,				
	document include proper clause?	52.234-4				
C.78	If R&D contract for Phase II, III or	NCI Workform				
	IV clinical trial, is clause titled					
	"Registration of Clinical Trials in					
	the Government Database" included					
	as appropriate?					
C.79	Is there evidence of an internal file	NIH Manual				
	review of contract and	6304.71				
	documentation?					
C.80	Is draft FedBizOpps Award Notice	FAR 5.301				
	in file?	(required >\$25K)				

No.	Action Item	FAR/HHSAR/	Yes	No	N/A	Comments
		NIH Policy Part				
C.81	Is draft public award announcement	FAR 5.303(a),				
	in file ("Congressional Liaison	HHSAR				
	Office")?	305.303(a)				
		(required >				
		\$3.5M)				
C.82	Has CO assured that contractor is in CCR?	FAR 4.1103				
C.83	Has CO entered contract into	FAR 4.604(b);				
	Prism/Compusearch (NBS) and	HHSAR 304.602				
	completed DCIS documentation					
	within the required timeframes?					
C.84	Has source selection information	FAR 3.104-4				
G 0.5	been appropriately marked?					
C.85	If requested, was compliant	FAR 15.505				
	preaward debriefing conducted, and					
0.06	documented?	EAD				
C.86	Are contractor's Representations	FAR				
	and Certifications complete and	4.803(a)(11),				
	accurate or, if used, are electronic	4.1201, 15.204-5				
	Reps & Certs referenced in contract file adequate?					
C.87	If applicable, are performance-	FAR 32.1004(b).				
C.67	based finance payments established	32.104				
	in contract only to extent actually	32.104				
	needed for performance?					
C.88	If letter contract and based on price	FAR 16.603-2(b)				
2.00	competition, price ceiling	and (c)				
	established and is definitization	(-)				
	schedule included in contract?					

No.	Action Item	FAR/HHSAR/	Yes	No	N/A	Comments
		NIH Policy Part				
C.89	Is there written assurance that	FAR 32.702,				
	adequate funds are available (funds	32.703-2				
	certification), or is the award					
	conditioned upon availability of					
	funds?					
C.90	Has clearance for foreign contract	FAR 25.802,				
	been received, if applicable?	HHSAR 325,				
		NIH Manual				
		6325-1				
C.91	Has animal clearance been	NIH Manual				
	obtained?	6380-2				
C.92	If advance payments are appropriate	FAR 32.402(c)				
	is executed D&F in file?					
C.93	Is use of incremental funding	HHSAR 332.702				
	appropriate?					
C.94	Is contract-specified timetable	HHSAR 332.703-				
	consistent with planned phases or	1(b)(2)				
	increments and corresponding					
	allotments of funds?					
C.95	At time of award, if less than the	HHSAR 332.703-				
	first year of performance funded,	1(b)(5)				
	did the CO document file as to why					
	it was advantageous to Gov't. & did					
	the funding cover a complete phase					
	or increment of performance?					
C.96	Does contract contain precise	HHSAR 332.703-				
	requirements for progress reports, if	1(b)(7)				
G 0.5	applicable?	7.7.4.4.60				
C.97	If letter contract, is it appropriate	FAR 16.603,				
	and compliant with requirements?	HHSAR 316.603				

No.	Action Item	FAR/HHSAR/ NIH Policy Part	Yes	No	N/A	Comments
C.98	Is source selection proper and sufficiently documented?	FAR 15.308				
C.99	Does contract reflect agreement of the parties?	HHSAR 315.371(a)(2)				
C.100	If appropriate, are CAS clauses included in contract?	FAR 30.201 -4, Appendix 9903-2				
C.101	If required, is consultant certification in file?	FAR 9.504-4, NIH Manual 6009-1				
C.102	Has written postaward notice been provided within 3 days after contract award to each offer in competitive range but not selected for award and has debriefing been held if requested by unsuccessful offerors?	FAR 15.503(b), 15.505, 15.506				
C.103	Has preaward notice been made to offerors when using HUBZone procedures or service-disabled veteran-owned procedures?	FAR 15.503(a)(2)(i)(C) and (D)				
C.104	Has preaward notice been given to offerors if SDB concern received benefit based on disadvantaged status?	FAR 15.502(a)(2)(i)(B)				
C.105	If applicable, is there a record of the debriefings in the contract file?	FAR 15.506				

SECTION D – Contract Administration

No.	Action Item	FAR/HHSAR/ NIH Policy Part	Yes	No	N/A	Comments
		Administrative Actions				
D.1	Was COTR/PO designated in writing?	NCI Contract Workform				
D.2	Does COTR/PO have training in accordance with HHSAR requirements or has a waiver obtained?	HHSAR 307.170 and 307.170-1 and 2				
D.3	Has compliant postaward debriefing been held if requested and is there a record in the file?	FAR 15.506				
D.4	If FAR 52.219-28 was included in contract, did contractor represent its size status upon occurrence of events stipulated?	FAR 19.308(d), 52.219-28(b)				
D.5	If letter contract or undefinitized action, was contract definitized in a timely manner?	FAR 16.603				
D.6	Is contractor size status representation validated or updated in the ORCA and its data in the CCR also updated to reflect current status?	FAR19.308(d), FAR 52.219-28				
D.7	If CO was notified of possible contractor violation of Federal criminal law, have proper procedures been followed, including coordination with OIG?	FAR 3.1003(b)				

No.	Action Item	FAR/HHSAR/	Yes	No	N/A	Comments
D.8	If task/delivery order over \$5M under IDIQ, does requirement sent under fair opportunity provide proper information?	FAR 16.505(a)(9)(b) (iii)				
D.9	If task/delivery order under IDIQ in excess of \$5M, has CO properly notified unsuccessful offerors?	FAR 16.505(b)(4)				
		Post Award Protests				
D.10	If protest after award, has CO determination for agency protest been handled timely?	FAR 33.104				
D.11	If protest after award, has CO obtained concurrence from Protest Control Officer (and OGC, if agency protest)?	HHSAR 333.103(f)(1) and (2)(iii)				
D.12	If protest after award, has CO followed appropriate protest procedures in response to protest filed with GAO?	FAR 33.104, HHSAR 333.104 NIH Manual 6033-1 & 6033-2				
D.13	If protest after award of task/delivery order under IDIQ, and if <\$10M, is it only on the basis that order increases scope, period, or maximum value of contract?	FAR 16.505(a)(9)(i)				
D.14	If applicable, has D&F to allow performance been properly approved?	FAR 33.104(c) & (d), HHSAR 333.104(c) & (d), NIH Manual 6033-2				

No.	Action Item	FAR/HHSAR/ NIH Policy Part	Yes	No	N/A	Comments
		Modifications and Change Orders				
D.15	Are contract modifications properly documented, citing correct authority and funding, within scope, and issued properly by a warranted CO as unilateral or bilateral?	FAR 43				
D.16	If modification is for new work, is approved JOFOC in file?	FAR 6.303, HHSAR 306-303, JOFOC Desk Guide				
D.17	Did CO ensure availability of funds prior to issuing modification/change order?	FAR 43.105				
D.18	If change order issued, is it within scope, within parameters of Changes clause, signed by a warranted CO (within his/her authority)?	FAR 43.2				
D.19	If change order issued, was equitable adjustment definitized?	FAR 43.2				
D.20	If change orders have been executed, were they definitized in a timely manner?	FAR 43.204				
D.21	Does supplemental agreement definitizing a change order include a Contractor's Statement of Release?	FAR 43.204(c)				

No.	Action Item	FAR/HHSAR/ NIH Policy Part	Yes	No	N/A	Comments
D.22	Where applicable, are contractor's requests for equitable adjustment processed in accordance with FAR 50.103 and is there a compliant approval/denial Memorandum of Decision in file?	FAR 50.103-6				
D.23	Has contract modification been entered into Prism/Compusearch (NBS) and FPDS (through DCIS) including mods for change in size status, as applicable?	FAR 4.604(b)(5); NBS				
D.24	If a contract with options and a subcontracting plan was required, or if a modification to a contract, have revised subcontracting goals been negotiated?	FAR 19.705-2				
		Claims				
D.25	Are claims/disputes handled properly?	FAR 33.2, HHSAR 333.2				
D.26	Has CO made a timely response to contractor dispute under CDA?	FAR 33.211(c)- (f)				
D.27	Has contractor submitted certified claim under CDA?	FAR 33.207				
D.28	Has CO consulted OGC in resolving dispute under CDA?	HHSAR 333.211				
D.29	Has CO successfully resolved claim under CDA?	FAR 33.210				
D.30	Has CO rendered final decision IAW FAR & agency provisions?	FAR 33.211, HHSAR 333.211				

No.	Action Item	FAR/HHSAR/ NIH Policy Part	Yes	No	N/A	Comments
D.31	If applicable, is alternate dispute resolution process used?	FAR 33.214				
		Management				
D.32	If mistake after award, have appropriate procedures been followed?	FAR 15.508				
D.33	If options included in contract, have they been executed properly and documented?	FAR 17.207				
D.34	Have contractor's invoices been reviewed/approved/disapproved in a timely manner?	FAR 32				
D.35	If termination for convenience/default deemed necessary, was process handled properly?	FAR 49				
D.36	If novation/change of name agreement requested, was process handled properly?	FAR 42.12				
D.37	Are past performance evaluations (interim/final) in file?	FAR 42.1502				
D.38	Is there compliance with acceptance/inspection/quality assurance requirements?	FAR 46.102				
D.39	If commercial, is there compliance with commercial quality assurance/inspection requirements?	FAR 12.208				

No.	Action Item	FAR/HHSAR/	Yes	No	N/A	Comments
		NIH Policy Part				
D.40	If cost overrun, has coordination	HHSAR				
	taken place with program office,	342.7101,				
	additional funds request received	342.7102				
	from contractor, statement from					
	program office to fund/terminate					
	contract, fixed fee unadjusted?					
D.41	Have debarment/suspension	FAR 9.4, HHSAR				
	procedures been properly followed?	309.4				
D.42	Has there been consent to	FAR 44.201				
	subcontracts or approved system?					
D.43	Are subcontracting reports,	FAR				
	including report required at the	19.704(a)(10),				
	expiration of the contract, submitted	19.705-6, 19.705-				
	by prime contractor and	7, 19.706				
	subcontractors (using eSRS) and	(Required for				
	have they been evaluated?	Large Bus.				
		>\$550K)				
D.44	If applicable, has award fee	FAR				
	evaluation been conducted	16.404(a)(2),				
	properly?	16.405(2)(b)(3)				
D.45	Was an analysis conducted of the	FAR 45.105				
	contractor's property management					
	policies, procedures, practices and					
	systems, and if noncompliant, did					
	CO provide written notification as					
	required?					
D.46	Has Value Engineering Change	FAR 48.103				
	Proposal (VECP) been received and					
	processed appropriately?					

SECTION E – Contract Closeout

No.	Action Item	FAR/HHSAR/ NIH Policy Part	Yes	No	N/A	Comments
E.1	Has final payment/settlement been made?	FAR 4.804-5				
E.2	Have administrative closeout procedures been accomplished?	FAR 4.804-5				
E.3	Has contract completion statement been prepared?	FAR 4.804-5(b)				
E.4	Has disposition of GFP/GFE been addressed?	FAR 45.603				
E.5	Has final past performance evaluation been received?	FAR 42.1502 (over \$100K)				
E.6	If applicable, has a contract audit in accordance with agency procedures been performed?	HHSAR 304.804- 70				
E.7	Have storage, handling & disposal of contract files been accomplished in accordance with agency procedures?	FAR 4.805				
E.8	Has closeout been accomplished in a timely manner?	FAR 4.804-1				
E.9	Has the HHS GWAC contract been used to accomplish closeout, or has a justification been prepared for the file?	HHS guidance				
E.10	Have excess funds been deobligated and returned to customer?	FAR 4.804-5				